143 related articles for article (PubMed ID: 1906778)
41. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
42. [Combination chemotherapy of mitomycin C and cytosine arabinoside in superficial bladder tumors. 1. Evaluation of intravesical infusion therapy].
Ikeuchi T; Onodera Y; Kai Y
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2145-51. PubMed ID: 6414383
[TBL] [Abstract][Full Text] [Related]
43. [Cytotoxic effect of oncolytic virus combined with mitomycin against human bladder cancer cells in vitro and in vivo].
Zhao GZ; Tan WL; Zheng SB; Wu YD; Xie Y; Zhu WH
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1623-5, 1628. PubMed ID: 17121717
[TBL] [Abstract][Full Text] [Related]
44. Cross-resistance of human multidrug-resistant cells to mitomycin C.
Yusa K; Sato W; Yamazaki A; Tsukahara S; Tsuruo T
Anticancer Res; 1991; 11(3):1301-4. PubMed ID: 1909515
[TBL] [Abstract][Full Text] [Related]
45. Pharmacological determinants of 9-aminocamptothecin cytotoxicity.
Li ML; Horn L; Firby PS; Moore MJ
Clin Cancer Res; 2001 Jan; 7(1):168-74. PubMed ID: 11205905
[TBL] [Abstract][Full Text] [Related]
46. Comparative studies on the action of 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C and of mitomycin C on cultured HL-60 cells and isolated phage and plasmid DNA.
Ishioka C; Kanamaru R; Konishi Y; Ishikawa A; Shibata H; Wakui A
Cancer Chemother Pharmacol; 1990; 26(2):117-21. PubMed ID: 2112051
[TBL] [Abstract][Full Text] [Related]
47. Histocultures of patient head and neck tumors for pharmacodynamics studies.
Au JL; Wientjes MG; Rosol TJ; Koolemans-Beynen A; Goebel EA; Schuller DE
Pharm Res; 1993 Oct; 10(10):1493-9. PubMed ID: 8272413
[TBL] [Abstract][Full Text] [Related]
48. A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect.
Millenbaugh NJ; Wientjes MG; Au JL
Cancer Chemother Pharmacol; 2000; 45(4):265-72. PubMed ID: 10755313
[TBL] [Abstract][Full Text] [Related]
49. Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line.
Singh SV; Scalamogna D; Xia H; O'Toole S; Roy D; Emerson EO; Gupta V; Zaren HA
Int J Cancer; 1996 Mar; 65(6):852-7. PubMed ID: 8631603
[TBL] [Abstract][Full Text] [Related]
50. The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines.
van der Heijden AG; Jansen CF; Verhaegh G; O'donnell MA; Schalken JA; Witjes JA
Eur Urol; 2004 Nov; 46(5):670-4. PubMed ID: 15474281
[TBL] [Abstract][Full Text] [Related]
51. Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia.
Bando T; Kasahara K; Shibata K; Numata Y; Heki U; Shirasaki H; Iwasa K; Fujimura M; Matsuda T
J Cancer Res Clin Oncol; 1996; 122(1):21-6. PubMed ID: 8543588
[TBL] [Abstract][Full Text] [Related]
52. Anticarcinogenic and antimitotic effects of Turkish propolis and mitomycin-C on tissue cultures of bladder cancer.
Erhan Eroğlu H; Ozkul Y; Tatlisen A; Silici S
Nat Prod Res; 2008; 22(12):1060-6. PubMed ID: 18780247
[TBL] [Abstract][Full Text] [Related]
53. Biochemical mechanism of cross-resistance to paclitaxel in a mitomycin c-resistant human bladder cancer cell line.
Bleicher RJ; Xia H; Zaren HA; Singh SV
Cancer Lett; 2000 Mar; 150(2):129-35. PubMed ID: 10704734
[TBL] [Abstract][Full Text] [Related]
54. Drug resistance restricts the efficacy of short term low dose Mitomycin-C treatment in UMUC-3 bladder cancer cells.
Gul M; Goktas S; Kars MD; Kaynar M
Arch Esp Urol; 2018 Nov; 71(9):783-793. PubMed ID: 30403381
[TBL] [Abstract][Full Text] [Related]
55. Mechanism of differential sensitivity of human bladder cancer cells to mitomycin C and its analogue.
Xu BH; Gupta V; Singh SV
Br J Cancer; 1994 Feb; 69(2):242-6. PubMed ID: 8297721
[TBL] [Abstract][Full Text] [Related]
56. Pharmacologic effects of paclitaxel in human bladder tumors.
Au JL; Kalns J; Gan Y; Wientjes MG
Cancer Chemother Pharmacol; 1997; 41(1):69-74. PubMed ID: 9443616
[TBL] [Abstract][Full Text] [Related]
57. Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C.
Kobayashi E; Okabe M; Kono M; Arai H; Kasai M; Gomi K; Lee JH; Inaba M; Tsuruo T
Cancer Chemother Pharmacol; 1993; 32(1):20-4. PubMed ID: 8096440
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic effect of an aromatic retinoic acid analog on rats with bladder carcinoma upon administration alone or in combination with mitomycin C.
Fujita J; Miyakawa M; Tokuda H; Yoshida O
Gan; 1982 Apr; 73(2):285-8. PubMed ID: 6288501
[TBL] [Abstract][Full Text] [Related]
59. High-dose chemotherapeutics of intravesical chemotherapy rapidly induce mitochondrial dysfunction in bladder cancer-derived spheroids.
Yoshida T; Okuyama H; Nakayama M; Endo H; Nonomura N; Nishimura K; Inoue M
Cancer Sci; 2015 Jan; 106(1):69-77. PubMed ID: 25363302
[TBL] [Abstract][Full Text] [Related]
60. Cytotoxic activity of 7-N-(2-((2-(-gamma-L-glutamylamino)- ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns.
Dirix LY; Gheuens EE; van der Heyden S; van Oosterom AT; De Bruijn EA
Anticancer Drugs; 1994 Jun; 5(3):343-54. PubMed ID: 7919460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
